IDOSE TR
Drug
Glaukos Corporation
Total Payments
$1.0M
Transactions
1,322
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $1.0M | 1,322 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.0M | 1,322 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% | Glaukos Corporation | $1.0M | 0 |
| Multicenter Randomized Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | Glaukos Corporation | $3,824 | 0 |
| Prospective, Non-Randomized, Open-Label, Multi-Center, Single Arm Study of Exchange of Travoprost Intraocular Implant | Glaukos Corporation | $725.00 | 0 |
Top Doctors Receiving Payments for IDOSE TR
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $1.0M | 1,322 |
Ad
Manufacturing Companies
- Glaukos Corporation $1.0M
Product Information
- Type Drug
- Total Payments $1.0M
- Total Doctors 0
- Transactions 1,322
About IDOSE TR
IDOSE TR is a drug associated with $1.0M in payments to 0 healthcare providers, recorded across 1,322 transactions in the CMS Open Payments database. The primary manufacturer is Glaukos Corporation.
Payment data is available from 2023 to 2023. In 2023, $1.0M was paid across 1,322 transactions to 0 doctors.
The most common payment nature for IDOSE TR is "Unspecified" ($1.0M, 100.0% of total).
IDOSE TR is associated with 3 research studies, including "Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5%" ($1.0M).